|
| Status |
Public on Mar 29, 2012 |
| Title |
Transcriptome Alteration in the Diabetic Heart by Rosiglitazone: Implications for Cardiovascular Mortality |
| Organism |
Mus musculus |
| Experiment type |
Expression profiling by array
|
| Summary |
The type 2 diabetes medication, rosiglitazone, has come under scrutiny for possibly increasing the risk of cardiac disease and death. To investigate the effects of rosiglitazone on the diabetic heart, we performed cardiac transcriptional profiling of a murine model of type 2 diabetes, the C57BL/KLS-leprdb/leprdb (db/db) mouse. We compared cardiac gene expression profiles from three groups: untreated db/db mice (db-c), db/db mice after rosiglitazone treatment (db-t), and non-diabetic db/+ mice.
|
| |
|
| Overall design |
Mice were divided into three groups: Non-diabetic controls (db/+), untreated diabetic controls (db-c), and rosiglitazone-treated diabetic mice (db-t). Whole-heart RNA from five mice from each of the three groups after four months with or without treatment was used for microarray analysis.Universal Reference RNAs for mouse (Stratagene, La Jolla, CA) were purchased as microarray reference controls.
|
| |
|
| Contributor(s) |
Wilson KD, Wagner R, Li Z, Nestorova G, Hirschberg DL, Wu JC |
| Citation(s) |
18648539 |
| |
| Submission date |
Mar 28, 2012 |
| Last update date |
May 10, 2018 |
| Contact name |
Kitchener D. Wilson |
| E-mail(s) |
[email protected]
|
| Organization name |
Stanford University
|
| Street address |
S140 Grant Bldg
|
| City |
Stanford |
| State/province |
CA |
| ZIP/Postal code |
94305 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL4134 |
Agilent-014868 Whole Mouse Genome Microarray 4x44K G4122F (Feature Number version) |
|
| Samples (15)
|
|
| Relations |
| BioProject |
PRJNA157141 |
Less...
More...